Why the study?
Does treatment with less than 50% of recommended dose of ACE-inhibitors/ARBs and beta-blockers increase the risk of death and/or heart failure hospitalization compared to reaching ≥100% in patients with HFrEF?
Does treatment with less than 50% of recommended dose of ACE-inhibitors/ARBs and beta-blockers increase the risk of death and/or heart failure hospitalization compared to reaching ≥100% in patients with HFrEF?
Suboptimal dosing (<50% of recommended) of ACE-inhibitors/ARBs and beta-blockers in HFrEF is associated with worse clinical outcomes compared to achieving target doses.
No takes yet. Share an insight, caveat, or question.
Suboptimal dosing associated with higher HFrEF risk; hypothesis-generating and should not yet change practice.
Ouwerkerk et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: